Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $176
نيوروكرين بيوساينسز
Neurocrine Biosciences, Inc. NBIX | 0.00 |
Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:
NBIX) with a Outperform and raises the price target from $166 to $176.
